Adverse events and estimated costs with the combination of ipilimumab and nivolumab in metastatic melanoma patients.

被引：1

作者：

Moura, Bianca Gautron

Gerard, Camille Lea

Testart, Nathalie

Caikovsky, Marian

Wicky, Alexandre M.

Aedo-Lopez, Veronica

Berthod, Gregoire

Homicsko, Krisztian

Prior, John

Dromain, Clarisse

Kandalaft, Lana E.

Cuendet, Michel A.

Michielin, Olivier

机构：

[1] Univ Lausanne, Dept Oncol, Lausanne, Switzerland

[2] Univ Lausanne Hosp, Nucl Med, Lausanne, Switzerland

[3] Univ Lausanne Hosp, CHUV, Lausanne, Switzerland

[4] CHUV Univ Hosp, Dept Radiol, Lausanne, Switzerland

[5] Univ Lausanne, Ludwig Inst Canc Res Lausanne, Lausanne, Switzerland

[6] Lausanne Univ Hosp, Lausanne, Switzerland

[7] Lausanne Univ Hosp CHUV, Ctr Personalized Oncol, Lausanne, Switzerland

[8] Swiss Inst Bioinformat, Mol Modeling Grp, Lausanne, Switzerland

[9] Dept Phy, Lausanne, Switzerland

[10] Lausanne Univ Hosp CHUV, Ctr Personalized Oncol, Lausanne, Switzerland

[11] Swiss Inst Bioinformat, Mol Modeling Grp, Lausanne, Switzerland

来源：

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.e21529

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e21529

引用

页数：3